A targeted approach to maintenance of tumour response. Clinical and translational studies in metastatic colorectal cancer.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Fler filtreringsmöjligheter
  1. 2017
  2. 2016
  3. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

    Helga Hagman, Jan-Erik Frödin, Åke Berglund, Jan Sundberg, Lene Vestermark, Maria Albertsson, Eva Fernebro & Anders Johnsson, 2016 jan, I : Annals of Oncology. 27, 1, s. 140-147

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  4. 2013
  5. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

    Anders Johnsson, Helga Hagman, Jan-Erik Frödin, Åke Berglund, N. Keldsen, Eva Fernebro, J Sundberg, R De Pont Christensen, K-L Garm Spindler, D Bergström & A Jakobsen, 2013, I : Annals of Oncology. 24, 9, s. 2335-2341

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift